Utah Just Let an Algorithm Write Prescriptions - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Utah Just Let an Algorithm Write Prescriptions

Physician oversight waived in state sandbox; federal review status unclear

  • By

  • Kerri Miller

  • April 13, 2026

  • 3 min

Share

Clinical Scorecard: Utah Just Let an Algorithm Write Prescriptions

At a Glance

CategoryDetail
Condition
Key MechanismsUtilizes an AI system to conduct comprehensive medical assessments and prescribe medications, but lacks peer-reviewed validation.
Target Population
Care Setting

Key Highlights

  • Internal data shows 99.2% concordance with clinician decisions, but lacks peer-reviewed validation and was conducted in a different clinical context.

Guideline-Based Recommendations

Diagnosis

  • Require robust evidence of safety and effectiveness before AI prescribing integration.
  • Ensure FDA review of AI prescribing systems.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Individuals needing prescription renewals and those with limited access to primary care.

        AI systems may enhance medication adherence but require validation in clinical settings.

        Clinical Best Practices

        • Incorporate AI prescribing only after establishing safety and effectiveness through clinical trials.
        • Engage stakeholders in discussions about the ethical implications of AI in healthcare, including transparency in clinical decision-making.

        Related Resources & Content

        Original Source(s)

        Utah Just Let an Algorithm Write Prescriptions

        • by Kerri Miller

        • April 13, 2026

        Related Content

        Can SGLT2 Inhibitors Affect Dementia?

        A target trial emulation using Veterans Affairs electronic health records examined neuropsychiatric outcomes associated with SGLT2 inhibitor use.

        Are GLP-1s Linked to Optic Neuropathy?

        A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.

        Serostatus May Modify RA Activity–CV Link

        Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.